CD133 Innovation Limited (CD133) was founded in 2019 in Hong Kong by Prof. Ken KL Yung (DPhil) and Dr. Cathy NP Lui (PhD) with the goal to translate their academic innovation into nanommaterial-based technologies. Our patented technology advanced the CTC test into a highly precise, simple, and safe early cancer detection service, which can overcome the shortcomings of the current available liquid biopsy for cancer detection and monitoring.
We are dedicated to:
CD133 is surrounded by a patch of professionals from different areas. We are dedicated to provide high quality, precise and safe technologies for our clients.